Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Acquired Immune Deficiency Syndromes 2002-Aug

A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Tautan disimpan ke clipboard
Jacob Lalezari
Janette Lindley
Sharon Walmsley
Baruch Kuppermann
Martin Fisher
Dorothy Friedberg
Richard Lalonde
Sophie Matheron
Leopoldo Nieto
Francesca J Torriani

Kata kunci

Abstrak

Valganciclovir, an oral prodrug of the anti-cytomegalovirus (CMV) agent ganciclovir, was evaluated in a single-arm open-label safety study. AIDS patients (median CD4 lymphocyte count of 140 cells/microL) with treated CMV retinitis (N = 212) received 900-mg once-daily valganciclovir maintenance therapy with courses of 900-mg twice-daily valganciclovir induction therapy as needed to treat progression. After a median treatment duration of 372 days, the adverse event profile was similar to that reported for intravenous (IV) and oral ganciclovir. Adverse event rates of note were diarrhea (35%), nausea (23%), fever (18%), neutropenia (absolute neutrophil count <500 cells/microL) (10%), and anemia (hemoglobin <8.0 g/dL) (12%). Consistent with prior treatment studies of oral ganciclovir, IV catheter-related adverse events were uncommon (6%) and lower than previously reported for IV ganciclovir. The mortality rate was 0.072 deaths per patient-year. Progression of CMV retinitis occurred in 17% of patients during the study treatment period, usually in association with a low CD4 cell count. Other than a higher than expected frequency of oral candidiasis (17%), no clinical toxicities or laboratory abnormalities occurred during treatment with valganciclovir that have not been observed during treatment with ganciclovir.

Bergabunglah dengan
halaman facebook kami

Database tanaman obat terlengkap yang didukung oleh sains

  • Bekerja dalam 55 bahasa
  • Pengobatan herbal didukung oleh sains
  • Pengenalan herbal melalui gambar
  • Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
  • Baca publikasi ilmiah yang terkait dengan pencarian Anda
  • Cari tanaman obat berdasarkan efeknya
  • Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten

Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan

Google Play badgeApp Store badge